Preclinical data provides mechanistic support but does not change the binary risk profile of a clinical-stage biotech. The key catalyst is the 16-week topline data expected in Q4 2026. Monitor for any financing needs given the $11M market cap and ongoing clinical trials.
Price Chart
Executive Summary
MetaVia Inc. announced preclinical tissue distribution study results for its obesity drug candidate DA-1726, showing highest exposure in adipose tissue and prolonged retention supporting once-weekly dosing. The company also guided for upcoming 16-week topline data in Q4 2026 and 24-week results in Q1 2027. This is a non-financial, pipeline-progress update for a clinical-stage biotech with an $11M market cap, providing mechanistic support for previously reported clinical data but no new clinical efficacy or safety results.
Key Facts
- Preclinical study showed DA-1726-derived radioactivity highest in adipose tissue and prolonged retention through 144 hours.
- Minimal radioactivity detected in central nervous system, consistent with limited brain penetration of peptide therapies.
- Company expects to report 16-week topline data from ongoing 24-week dose-titration study in Q4 2026, and 24-week topline results in Q1 2027.
- Previously reported Phase 1 data showed 48 mg dose achieved mean 9.8 cm waist circumference reduction after 8 weeks.
- Market cap is $11M with 88% analyst bullish consensus.
Financial Impact
No financial data reported; preclinical study update with no revenue or earnings impact.
Risk Factors
- Preclinical results may not predict clinical outcomes.
- Company has history of net losses and may need additional capital to fund operations.
- Binary risk from upcoming clinical data readouts in Q4 2026 and Q1 2027.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-106156 |
| Document: mtva-20260909xex99d1.htm | 0001104659-26-106156 |
| Document: 0001104659-26-106156-index-headers.html | 0001104659-26-106156 |
| Document: 0001104659-26-106156-index.html | 0001104659-26-106156 |
| Document: 0001104659-26-106156.txt | 0001104659-26-106156 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 13, 2026 13d ago | 3 | $1.36 | awaiting T+20 | — | $1.22 (−10.66%) |
Oct 13, 2026 13d ago | 8-K | $1.43 | awaiting T+20 | — | $1.22 (−15.03%) |
Sep 9, 2026 6w ago | 8-K | $1.74 $1.46 | ▼ −16.09% | ▼ −18.04% | $1.22 (−30.17%) |
Jul 9, 2026 15w ago | 8-K | $1.73 $1.45 | ▼ −16.18% | ▼ −18.43% | $1.22 (−29.77%) |
Jul 2, 2026 16w ago | 424B5 | $1.48 $1.44 | ▲ +2.70% | ▲ +2.29% | $1.22 (+17.91%) |
Jun 8, 2026 20w ago | 8-K | $1.89 $1.58 | ▼ −16.40% | ▼ −17.85% | $1.22 (−35.71%) |
Jun 8, 2026 20w ago | 8-K | $2.22 $1.51 | ▼ −31.98% | ▼ −33.61% | $1.22 (−45.27%) |
May 27, 2026 21w ago | 8-K | $3.34 $1.53 | ▼ −54.19% | ▼ −52.29% | $1.22 (−63.62%) |
May 18, 2026 23w ago | 8-K | $1.11 $1.65 | ▲ +48.65% | ▲ +47.07% | $1.22 (+9.46%) |
May 14, 2026 23w ago | 8-K | $1.11 $1.71 | ▲ +54.05% | ▲ +51.94% | $1.22 (+9.46%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers